Compare ESPR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | CDNA |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.1M | 712.2M |
| IPO Year | 2013 | 2014 |
| Metric | ESPR | CDNA |
|---|---|---|
| Price | $3.70 | $18.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $6.86 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 7.0M | 881.0K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | $303,802,000.00 | ★ $357,998,000.00 |
| Revenue This Year | $25.45 | $14.11 |
| Revenue Next Year | N/A | $12.00 |
| P/E Ratio | ★ N/A | $15.25 |
| Revenue Growth | 2.83 | ★ 14.46 |
| 52 Week Low | $0.69 | $10.96 |
| 52 Week High | $4.03 | $26.24 |
| Indicator | ESPR | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.61 | 62.70 |
| Support Level | $3.59 | $17.11 |
| Resistance Level | $3.91 | $19.80 |
| Average True Range (ATR) | 0.24 | 0.89 |
| MACD | 0.05 | 0.18 |
| Stochastic Oscillator | 77.74 | 73.23 |
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.